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The   incidence of cutaneous melanoma is steadily increasing, mainly in populations of European  origin  and  is  thus  
an  important  public  health  issue  throughout  the  world. Cutaneous  melanoma  is  a  malignancy  with  a  favorable  prognosis  if  it  presents  as  a localized  disease,  
but  with  a  dramatically  worse  prognosis  if  it  metastasizes.  No  effective  treatment  exists  for  the  group  of  melanoma  patients  with  metastasizing  disease,  
although  several  nonspecific  chemotherapy  regimens  and  immunotherapies  are  able  to  prolong survival  at  least  for  a  short  period  of  time.  Last  years  has  
started  a  new  area  in  the  treatment  using  BRAF  mutation  inhibitors, especially  for  patients  with  BRAF V600E  positive, so, also  in  melanoma  is  available  
targeted  therapy. This  new  treatment  plays  an  important  role  in  their  survival. The  aim  of  the  study:  to  evaluate  the  BRAF  mutation  in  patients  diagnosed  
with melanoma. Methods:  We  analised  BRAF  mutation  in  12  formaline -fixed  paraffine  embedded  (FFPE) tissue  of   patients  diagnosed  with  melanoma  from  
January  to  December  2014. Results: From  12  FFPE  tissue  we  found  67  % (n=8)  BRAF  V600E, 25 %  (n=3)  BRAF Wild  Type,  8%  (n=1)  BRAF  V600K. 
Conclusions:  BRAF  V600E  mutation  is   an  important  molecular  target  for  novel  therapeutic  approaches  in  area of targeted  therapy of melanoma patients. 
Patient with  unresectable  or  metastatic  melanoma, whith BRAF  V600E, can  use  BRAF – inhibitors, increasing their survival. 
 
 Introduction 
 Melanoma  is  a  malignant  pathology,  accounting   approximately  4%  of  skin cancers (1). Melanoma  
is  the  most  aggressive  form  of  skin  cancer, it remains  highly curable if it is detected  early:  5-year  survival  
is  approximately  90% overall  and  exceeds  98%  when  disease  is  detected  at  the  localized  stage  (84%  of  
cases) (2).  
 The  treatment  of  choice  for  early  melanoma, is  no  doubt  surgical resection, and  adjuvant  therapy  
with  alfa  interferon  in  stage  II  and  III  of  the  disease  (3). In advanced  stage, melanoma  is  an  aggressive  
disease  with  poor  prognosis. 
 Last  years new therapeutic approaches comes in this field using BRAF V600E inhibitors for  melanoma  
patients. 
 BRAF   is  a  serine  threonine  kinase  and  a  member  of  the   MAPK – pathway  (Mitogen – activated   
protein kinase),  which is responsible  for cell  growth,  survival, and differentiation.  BRAF is highly expressed  
in  melanocytes  and  neuronal  tissue, both  of  which  are  of  neural  crest  origin. 
 BRAF  gene   mutation  testing  has   an  important  tool  for  diagnosis,  prognosis, treatment,  and  
predicting  patient  outcome  in  response  to  targeted  therapy  for multiple cancer  types  (4). Since  August  
2011, FDA  (Food  Drug  administration)  has  approved Vemurafenib  (Zelboraf) – an oral inhibitor of BRAF 
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mutation, for patients with metastatic melanoma or unresectable melanoma  who  have  BRAF  V600E  mutation 
(5). 
 Which patients should be tested? 
 Option 1:  Test all melanoma  patient should be tested for BRAF mutation, regardless of stage, because 
BRAF mutation status does not change between  primary or metastatic melanoma (6,7). 
 Option 2:  Test Patients  (Stage  IIb or IIc)  who   have  a risk of  recurrence   40–70% , mainly  2–4  
years  after  the  initial diagnosis (8).  
 Option 3:  Test  Patients  diagnosed  with  Metastatic  melanoma. 
 Methods 
 In  this  study  were  involved  12  patients  diagnosed  during  2014,  with   cutaneous  malignant  
melanoma, or  lung  metastatic  melanoma  in  the  department  of  pathology  in  the  University  Hospital  
Center “Mother  Teresa”  and  in  the  University  hospital ”Shefqet  Ndroqi” – Tirana. Method  used  for  
evaluation  of  BRAF  mutation,  in  these  FFPE  tissue  was  Sanger  Sequencing  in  the  department  of  
molecular biology and pathology (University of  Ferrara). 
 Sanger Sequencing: PCR amplicons were generated usinë the following primers: 50  
AGGTGATTTTGGTCTAGCTACAG–30  and  reverse: 50 GTTGAGACCTTCAATGACTTTCTAG–30, and 
were analyzed  on  the  ABI  Genetic Analyzer  3130  XL  (Applied  Biosystems, Foster  City,  CA), using  the  
Big–Dye  terminator kit  v1.1 (Applied  Biosystems).  
 Analysis is made   using  SPSS,  version  16.0. A  p  value  less  than 0.05   was  considered  to  be  
statistically  significant. 
 Results 
 This  study   included  12  albanian  melanoma  patients. Patients  were  analised  according  to  male  
female  ratio, Breslow  thickeness, Clark  level, angiovascular  invasion, ulceration  and BRAF  status. The  table  
belows  shows  all  clinicopathologic  findings  (table  1): 
Table  1  Clinocopathological Characteristics of   the 12 Study  Patients 
Characteristic No. (%) 
Male 8 / 67% 
Female 4 / 33% 
Mean  age 66.3 years 
Range  (min-max) Min=45 / Max=90 
Clark  level  mean 3 
Breslow  mean (mm) 3,2 
Ulceration   
Yes 7 / 77% 
No 2 / 23% 
Histological  type   
Nodular melanoma     6 
Superficial  spreading     3 
Metastasis     3 
Angiovascular   invasion   
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Yes 7  /  59% 
No 5  /  41% 
Resection  margins   
Yes 10  /   84% 
No 2  /   16% 
 12  FFEP  tissue  underwent  Sanger  Senquencing  and  we  observed  that  67 %  (n=8)  of  patients  
were  BRAF (V600E),  25 %  (n=3)  were  BRAF  WT (wild  type), 8 %  (n=1) were  BRAF  (V600K),  
illustrated  as  in  figures  below ( Figure  1): 
      
a                                                                                b 
 
c 
Figure  1 -  a – V 600E  codon  resulting  from  a  single – nucleotide  mutation (GTG > GAG). 
                  -  b – V600  codon  showing  the  wild – type  GTG  sequence. 
                  -  c – V600K  codon  resulting  from  a  dinucleotide  mutation  (GTG > AAG). 
Table  2 
                
Age 
sex Diagnoza type BRAF/V600 
E 
BRAF/V600K BRAF/WT 
80 f melanoma nodulare positive     
67 m metastasis       Positive 
73 f melanoma nodulare   positive   
67 m melanoma superficial 
spreading 
positive     
53 m melanoma nodulare positive     
45 m melanoma nodulare positive     
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73 f metastasis   positive     
49 m melanoma nodulare     Positive 
72 f melanoma superficial 
spreading 
    Positive 
68 m melanoma superficial 
spreading 
positive     
90 m melanoma nodulare positive     
40 m metastasis   positive     
 Considering  histological type or metastatic  melanoma,  the BRAF V600E  mutation  was  detected  in  
4 (33%)  cases of nodular melanoma, 2 (17%%) cases  of  superficial spreading  melanoma  and 2 (17%)  cases 
in metastasis of lung (table 2). 
 Discussion 
 The aim of our study was to evaluate BRAF mutation in Albanian  melanoma patients and also,  to  
investigate possible associations between prognostic parameters such as Breslow depth, Clark level, age, gender, 
ulceration, and the presence of BRAF mutation, even the number  of samples is limited, because of the cost of  
the examination. 
 There is a significative  correlation between  Breslow and Clark level (p<0.05), but we did not find any 
statistically significant association between the presence of the mutation and histological subtype, gender, or  
age.  
 We found statistically significant association between ulceration and angiovascular invasion (p= 0.034). 
There is no significant association between BRAF mutation and the presence of ulceration, or angiovascular  
invasion. 
 In  our  study  the  most common type was nodular melanoma while  in literature  superficial spreading  
melanoma  was the most common histological  subtype (9,10). In our study BRAF V600 E was found in 67% of  
cases. The table below (Table 3) shows a review of literature about BRAF V600 E. 
Literature   review  of  different  studies  that  investigated  BRAF  mutations  in  melanomas. 
Reference No. of subjects/country BRAF V600E mutation 
frequency (%) 
Davies et al., 2002 (11)   34/USA, Italy, Hong Kong, England  55.9 
Gorden et al.2003 (12)  77/USA  40 
Libra et al.2005 (13)  19/Italy 63 
Goel et al.2006 (14)  58/USA 57 
Lee et al., 2006 (15)  35/USA 60 
Liu et al., 2007 (16)  251/Australia 45 
Venesio et al., 2008  (17) 18/Italy 72 
Viros et al., 2008 (18) ) 302/USA,Germany,Japan,South Korea 47 
Casula et al., 2009 (19)  35/Italy 31.4 
Lázár et al., 2009 (20)  74/Hungary 27 
Narita et al., 2009 (21)  71/USA and Australia 39 
Broekaert et al., 2010  (22)  350/Germany, Austria, USA 49.7 
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Ellison et al., 2010 (23)  163/Great Britain 41.1 
Scherer et al., 2010 (24)  179/Italy and Germany  17.3 
Rubinstein et al., 2010 (25) 138/USA 69 
Ellerhorst et al., 2011 (26)   223/USA 42.2 
Janku et al., 2011 (27)  52/USA  50 
Long et al., 2011  (28)  197/Australia  35.5 
Shibata et al., 2011 (29)  39/Japan 28.2 
Menzies et al., 2011 (30)  312/Australia 33.6 
Inumaru at al., 2014  (9)  77/Brasil 70.1 
 
 Conclusions 
 
 The detection of BRAF mutation in  melanoma,  has  emerged as a central factor in the stratification of  
melanoma patients to deploy various targeted therapies in advanced–stage  disease., patients with BRAF V600E, 
can use BRAF–inhibitors, improving their quality of life and their  survival.  
 Albeit the sample is relatively small and the time length of the study is short, it is worth mentioning  
that other financial support are needed to improve our research in the area of molecular events of Albanian  
melanoma patients, to help and improve their quality of life.  
 
References 
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep-Oct. 60(5):277-
300.[Medline]. 
2. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al (eds). SEER Cancer 
Statistics Review 1975-2009. Table 16. 
3. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant 
therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 
1684. J Clin Oncol. 1996 Jan. 14(1):7-17. [Medline]. 
4. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med. 2011 Feb 24. 364(8):772-
4. [Medline]. 
5. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm268301.htm 
6. Libra M, Malaponte G, Navolanic PM et al. Analysis of BRAF mutation in primary and metastatic 
melanoma. Cell Cycle 2005; 4:1382–4 
7. Huntington JT, Shields JM, Der CJ et al. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK 
pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol 
Chem2004; 279:33168–76 
8. Marsden JR, Newton-Bishop JA, Burrows L et al. Revised U.K. guidelines for management of cutaneous 
melanoma. Br J Dermatol 2010; 163:238–56 
9. Genetics and Molecular Research 13 (2): 2840-2848 (2014) 
10. Ghosh P and Chin L (2009). Genetics and genomics of melanoma. Expert Rev. Dermatol. 4: 131. 
11. Davies H, Bignell GR, Cox C, Stephens P, et al. (2002). Mutations of the BRAF gene in human cancer. 
Nature 417: 949- 954. 
12. Gorden A, Osman I, Gai W, He D, et al. (2003). Analysis of BRAF and N-RAS mutations in metastatic 
melanoma tissues. Cancer Res. 63: 3955-3957. 
 Volume 4, issue 6, 2015  e-ISSN: 1857-8187   p-ISSN: 1857-8179                                                                                                            
Page | 69  
 Anglisticum Journal (IJLLIS), Volume: 4 | Issue: 6, June 2015 |  
 
13. Libra M, Malaponte G, Navolanic PM, Gangemi P, et al. (2005). Analysis of BRAF mutation in primary 
and metastatic melanoma. Cell Cycle 4: 1382-1384. 
14. Goel VK, Lazar AJ, Warneke CL, Redston MS, et al. (2006). Examination of mutations in BRAF, NRAS, 
and PTEN in primary cutaneous melanoma. J. Invest. Dermatol. 126: 154-160. 
15. Lee JH, Choi JW and Kim YS (2011). Frequencies of BRAF and NRAS mutations are different in 
histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br. J. Dermatol. 164: 776-784. 
16. Liu W, Kelly JW, Trivett M, Murray WK, et al. (2007). Distinct clinical and pathological features are 
associated with the BRAF[T1799A(V600E)] mutation in primary melanoma. J. Invest. Dermatol. 127: 900-
905. 
17. Venesio T, Chiorino G, Balsamo A, Zaccagna A, et al. (2008). In melanocytic lesions the fraction of BRAF 
V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation. Mod. Pathol. 21: 716-
726. 
18. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, et al. (2008). Improving melanoma classification by 
integrating genetic and morphologic features. PLoS Med. 5: e120. 
19. Casula M, Muggiano A, Cossu A, Budroni M, et al. (2009). Role of key-regulator genes in melanoma 
susceptibility and pathogenesis among patients from South Italy. BMC Cancer 9: 352. 
20. Lázár V, Ecsedi S, Szollosi AG, Toth R, et al. (2009). Characterization of candidate gene copy number 
alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma. Mod. Pathol. 
22: 1367-1378. 
21. Narita N, Tanemura A, Murali R, Scolyer RA, et al. (2009). Functional RET G691S polymorphism in 
cutaneous malignant melanoma. Oncogene 28: 3058-3068. 
22. Broekaert SM, Roy R, Okamoto I, van den Oord J, et al. (2010). Genetic and morphologic features for 
melanoma classification. Pigment Cell Melanoma Res. 23: 763-770. 
23. Ellison G, Donald E, McWalter G, Knight L, et al. (2010). A comparison of ARMS and DNA sequencing 
for mutation analysis in clinical biopsy samples. J. Exp. Clin. Cancer Res. 29: 132. 
24. Scherer D, Rachakonda PS, Angelini S, Mehnert F, et al. (2010). Association between the germline MC1R 
variants and somatic BRAF/NRAS mutations in melanoma tumors. J. Invest. Dermatol. 130: 2844-2848. 
25. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, et al. (2010). Incidence of the V600K mutation among 
melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor 
PLX4032. J. Transl. Med. 8: 67. 
26. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, et al. (2011). Clinical correlates of NRAS and 
BRAF mutations in primary human melanoma. Clin. Cancer Res. 17: 229-235. 
27. Janku F, Lee JJ, Tsimberidou AM, Hong DS, et al. (2011). PIK3CA mutations frequently coexist with RAS 
and BRAF mutations in patients with advanced cancers. PLoS One 6: e22769. 
28. Long GV, Menzies AM, Nagrial AM, Haydu LE, et al. (2011). Prognostic and clinicopathologic 
associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29: 1239-1246. 
29. Shibata T, Kokubu A, Miyamoto M, Sasajima Y, et al. (2011). Mutant IDH1 confers an in vivo growth in a 
melanoma cell line with BRAF mutation. Am. J. Pathol. 178: 1395-1402. 
30. Menzies AM, Visintin L, Chatfield MD, Carlino MS, et al. (2011). BRAF mutations by age-decade and 
body mass index in metastatic melanoma. J. Clin. Oncol. 2011 (29 Suppl): Abstract 10523. 
 
 Volume 4, issue 6, 2015  e-ISSN: 1857-8187   p-ISSN: 1857-8179                                                                                                            
Page | 70  
